Parth Rali, MD, Temple University Hospital, is looking forward to approaching pulmonary vascular diseases as a spectrum, especially when assessing pulmonary embolism and pulmonary hypertension, at ...
Orphai Therapeutics Inc. (“Orphai”), a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for patients with diseases of significant unmet need, today announced that ...
Type 2 diabetes and prediabetes can both significantly impact pulmonary health, highlighting the need for early detection and intervention. A new paper has highlighted the significant impact of type 2 ...
A new editorial published in Comprehensive Physiology underscores the critical importance of understanding heart-lung interactions in pulmonary vascular disease (PVD). Tim Lahm, MD, a pulmonologist ...
DURHAM, NC and LONDON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Polarean, a commercial-stage medical imaging company advancing functional MRI of the lungs, today announced the expansion of its Xenon MRI ...
Pulmonary arterial hypertension (PAH) is a rare condition that's difficult to treat. The hallmarks of the disease—narrowing of the arterioles and capillaries that deliver blood to the lungs—force the ...
A new editorial published in Comprehensive Physiology underscores the critical importance of understanding heart-lung interactions in pulmonary vascular disease (PVD). Tim Lahm, MD, a pulmonologist ...
Please provide your email address to receive an email when new articles are posted on . Researchers assessed how hormone exposures impact right ventricular function and pulmonary vascular disease in ...
Our one-year fellowship is offered to PGY-4 level candidates for training focused on heart failure management, pulmonary HTN, with cardiology ICU exposure. Fellows develop the ability to recognize and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback